Cleared Traditional

K953084 - ACCESS ULTRASENSITIVE INSULIN ASSAY

K953084 is the FDA 510(k) clearance for ACCESS ULTRASENSITIVE INSULIN ASSAY by Bio-Rad Laboratories, Inc.. It is a Class 1 Chemistry device (product code CFP) cleared through the Traditional 510(k) pathway after a 84-day FDA review.

K953084 · Bio-Rad Laboratories, Inc. · Chemistry device
Download Printable Device Report (PDF)
Optimized for regulatory review, auditing and printing
Sep 1995
Decision
84d
Days
Class 1
Risk

K953084 is an FDA 510(k) clearance for the ACCESS ULTRASENSITIVE INSULIN ASSAY. Classified as Radioimmunoassay, Immunoreactive Insulin (product code CFP), Class I - General Controls.

Submitted by Bio-Rad Laboratories, Inc. (Chaska, US). The FDA issued a Cleared decision on September 25, 1995 after a review of 84 days - a notably fast clearance cycle.

This device falls under the Chemistry FDA review panel, regulated under 21 CFR 862.1405 - the FDA in vitro diagnostics and chemistry framework. The Traditional 510(k) pathway establishes clearance through substantial equivalence to a legally marketed predicate device, without requiring clinical trial data.

Device pattern: Fast-track predicate clearance. Standard predicate reliance. The short review cycle indicates strong predicate alignment - the FDA found sufficient equivalence without extended technical review.

View all Bio-Rad Laboratories, Inc. devices

Submission Details

510(k) Number K953084 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received July 03, 1995
Decision Date September 25, 1995
Days to Decision 84 days
Submission Type Traditional
Review Panel Chemistry (CH)
Summary Summary PDF
Third-party Review No - reviewed directly by FDA
Combination Product No
PCCP Authorized No
Regulatory Context
Review time vs. panel average
4d faster than avg
Panel avg: 88d · This submission: 84d
Pathway characteristics
Predicate-based equivalence.

Device Classification

Product Code CFP Radioimmunoassay, Immunoreactive Insulin
Device Class Class 1 - General Controls
CFR Regulation 21 CFR 862.1405
What this classification means

Class I devices are subject to general controls only and most are exempt from 510(k) premarket notification. They represent the lowest regulatory burden in the FDA device framework.

Regulatory Peers - CFP Radioimmunoassay, Immunoreactive Insulin

All 14
Devices cleared under the same product code (CFP) and FDA review panel - the closest regulatory comparables to K953084.
IMX INSULIN
K920109 · Abbott Laboratories · May 1992
DSL INSULIN RIA (DSL 1600)
K914820 · Diagnostic Systems Laboratories, Inc. · Jan 1992
ENZYMUN TEST(R) INSULIN
K901135 · Boehringer Mannheim Corp. · Apr 1990
REP(TM) SPE PLUS-30 PROCEDURES
K896572 · Helena Laboratories · Jan 1990
PHARMACIA INSULIN RIA
K851071 · Pharmacia, Inc. · Apr 1985
WAKO INSULIN TEST
K823939 · Wako Chemicals USA, Inc. · Jan 1983